“I have never seen customers pulling forward demand because they don’t want excess inventory of finished products,” says Thermo Fisher’s CEO. Like other contract development and manufacturing organizations (CDMOs), Thermo Fisher firm stepped up during the pandemic and supported many of the vaccine and therapeutic projects, but – unlike some of its peers – the company remains confident it is in a good place to manage a post-pandemic demand drop, also known as the COVID cliff. “The business is having…

Eli Lilly expects “a substantial expansion” of capacity for its type 2 diabetes drug Mounjaro (tirzepatide) to come online around 2025 through internal investments and third-party support. Mounjaro, a once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor, received US Food and Drug Administration (FDA) in May this year. The product is a first in a new class of type 2 diabetes medication and is expected to become a blockbuster for Eli Lilly, and sales in its first full…

A day after announcing plans to expand a biomanufacturing site in Ireland, Pfizer has committed a second €1.2 ($1.25) billion for its Puurs, Belgium facilities. The site in Puurs, Belgium became central in Pfizer’s COVID-19 vaccine network, and underwent an expansion during the pandemic to install additional manufacturing and filling lines. Now the Big Pharma firm has committed a further €1.2 billion to the site, located 20km north of Brussels, over the next three years to expand production capacity, cold…